Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
First-in-Class Approval: Rezdiffra is the first and only FDA-approved therapy for MASH, granting a significant market advantage.
Addressing Unmet Need: Targets a large patient population with no previously approved treatment options, ensuring high demand.
Unique Mechanism of Action: Resmetirom's selective THR-beta agonism offers a novel and effective approach to MASH pathophysiology.
Risks
Commercial Launch Challenges: Despite FDA approval for resmetirom, successful market penetration, physician adoption, and patient adherence are not guaranteed, potentially impacting revenue targets.
Reimbursement & Payer Coverage Hurdles: Securing broad, favorable, and timely reimbursement from commercial and government payers for resmetirom is crucial for sales volume and can be a lengthy and uncertain process.
Intense Competitive Landscape: Madrigal faces significant current and future competition in the MASH therapeutic area from companies developing alternative treatments, which could limit market share and pricing flexibility.
Over a week ago
Jun 17, 4:17 PM
Jun 11, 6:40 AM
May 27, 8:12 AM
May 13, 9:38 AM
May 7, 7:56 AM
May 7, 6:53 AM
May 6, 4:55 PM
May 6, 7:31 AM
Mar 26, 2:57 PM
Feb 20, 7:22 AM
Feb 19, 7:06 AM
Feb 11, 5:07 AM
Feb 3, 6:49 AM
Jan 27, 4:26 PM
Jan 20, 5:55 AM
Jan 6, 7:53 AM
Jan 6, 7:44 AM